Developing better mouse models to study cisplatin-induced kidney injury.

Area of Science:

• Nephrology
• Oncology
• Translational Medicine

Background:

• Cisplatin is a crucial chemotherapy agent for various cancers.
• Nephrotoxicity, leading to acute kidney injury (AKI), is a significant dose-limiting side effect of cisplatin.
• AKI patients face higher mortality and increased risk of developing chronic kidney disease (CKD).
• Currently, no effective therapeutic interventions exist for AKI.

Purpose of the Study:

• To address the limitations of existing cisplatin-induced AKI mouse models.
• To develop and utilize more clinically relevant models for studying cisplatin nephrotoxicity.
• To facilitate the identification of novel therapeutic targets for AKI and CKD.

Main Methods:

• Developing novel preclinical models of cisplatin-induced kidney injury.
• Employing multiple low-dose cisplatin administration regimens over weeks.
• Mimicking patient dosing schedules in animal models.

Main Results:

• The new models successfully recapitulate the development of CKD following AKI.
• These models provide a more accurate representation of cisplatin's effects in patients.
• The improved models enhance the potential for discovering therapeutic strategies.

Conclusions:

• Clinically relevant models are essential for understanding cisplatin-induced kidney injury.
• Multiple low-dose cisplatin models are promising for AKI and CKD research.
• These models can accelerate the discovery of treatments for cisplatin nephrotoxicity.